DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Novartis (SIX:NOVN) reported a 24% surge in Q2 net income to $4 billion, driven by robust demand for key therapies like Kisqali, Entresto, and Kesimpta. Earnings per share rose 29% to $2.07, supported by a lower average share count. Revenue climbed 12% to $14.1 billion, with U.S. sales up 21% to $6.2 billion and international sales growing 6% to $7.8 billion.
The company saw strong volume growth of 12%, partially offset by a 2-point decline from generic competition. Pricing and currency each contributed a 1-point gain. Kisqali revenue soared 64% to $1.2 billion, Entresto jumped 24% to $2.4 billion, and Kesimpta rose 35% to $1.1 billion. Scemblix and Leqvio each posted $298 million in sales, up 82% and 64% respectively. Cosentyx grew 7% to $1.6 billion.
Operating income increased 21% to $4.9 billion, boosting the margin to 34.6% from 32.1%. Core operating income rose 20% to $5.9 billion, with the core margin improving to 42.2% from 39.6%. Gross profit rose to $11.5 billion, while cost of goods sold fell to 23.6% of sales.
R&D spending rose 15% to $2.7 billion. SG&A costs increased to $3.4 billion but declined slightly as a percentage of sales. Free cash flow surged 37% to $6.3 billion.
For H1 2025, Novartis posted a 29% increase in net income to $7.6 billion on $27.3 billion in sales. Free cash flow rose 46% to $9.7 billion. Oncology sales rose 22% to $4.3 billion, cardiovascular therapies surged 28% to $2.7 billion, and neuroscience grew 19% to $1.5 billion. Net debt increased to $23.8 billion following $13.3 billion in dividend and buyback outflows.
